Table of Content

1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 21
1.3.2 YEARS CONSIDERED FOR THE STUDY 22
1.4 CURRENCY USED FOR THE STUDY 22
1.5 MAJOR STAKEHOLDERS 22

2 RESEARCH METHODOLOGY 23
2.1 RESEARCH DATA 23
2.1.1 SECONDARY DATA 24
2.1.1.1 Secondary sources 25
2.1.2 PRIMARY DATA 26
2.2 MARKET ESTIMATION METHODOLOGY 26
2.2.1 END USER-BASED MARKET ESTIMATION 27
2.2.2 REVENUE MAPPING-BASED MARKET ESTIMATION 28
2.2.3 PRIMARY RESEARCH VALIDATION 28
2.3 DATA TRIANGULATION 29
2.4 RESEARCH ASSUMPTIONS 30
2.5 RESEARCH LIMITATIONS 30

3 EXECUTIVE SUMMARY 31

4 PREMIUM INSIGHTS 35
4.1 MARKET OVERVIEW 35
4.2 NEURODIAGNOSTICS MARKET, BY PRODUCT, 2019 VS. 2024 36
4.3 NEURODIAGNOSTICS MARKET SHARE, BY END USER AND REGION (2019) 37
4.4 NEURODIAGNOSTICS MARKET, BY CONDITION, 2019 VS. 2024 (USD MILLION) 38
4.5 NEURODIAGNOSTICS MARKET, BY COUNTRY 39

5 MARKET OVERVIEW 40
5.1 INTRODUCTION 40
5.2 MARKET DYNAMICS 40
5.2.1 DRIVERS 41
5.2.1.1 Increasing prevalence of neurological diseases & disorders 41
5.2.1.2 Technological advancements 41
5.2.1.3 Growing patient emphasis on effective and early disease diagnosis 42
5.2.1.4 Increasing number of diagnostic centers & hospitals 42
5.2.1.5 Advances in genomics and proteomics for the diagnosis of neurodegenerative disorders 43
5.2.2 RESTRAINTS 43
5.2.2.1 High cost of neurodiagnostic devices 43
5.2.2.2 Growing adoption of refurbished neurodiagnostic systems 44
5.2.3 OPPORTUNITIES 44
5.2.3.1 Increasing application of neurodiagnostic devices in clinical trials 44
5.2.3.2 Emerging markets 44
5.2.4 CHALLENGES 45
5.2.4.1 Dearth of skilled personnel 45

6 NEURODIAGNOSTICS MARKET, BY PRODUCT 46
6.1 INTRODUCTION 47
6.2 DIAGNOSTIC IMAGING SYSTEMS 47
6.2.1 GROWING NUMBER OF DIAGNOSTIC CENTERS TO DRIVE THE ADOPTION OF DIAGNOSTIC IMAGING SYSTEMS 47
6.2.1.1 MRI systems 49
6.2.1.2 EEG systems 51
6.2.1.3 CT scanners 53
6.2.1.4 PET scanners 54
6.2.1.5 EMG devices 56
6.2.1.6 Ultrasound imaging systems 58
6.2.1.7 MEG devices 59
6.2.1.8 Angiography systems 61
6.2.1.9 Other diagnostic imaging systems 63
6.3 CLINICAL DIAGNOSTIC INSTRUMENTS 64
6.3.1 INCREASING PUBLIC-PRIVATE INVESTMENTS ARE SUPPORTING
THE GROWTH OF THIS MARKET SEGMENT 64
6.3.1.1 PCR instruments 66
6.3.1.2 NGS instruments 68
6.3.1.3 Sanger sequencers 70
6.3.1.4 Other clinical diagnostic instruments 72
6.4 REAGENTS & CONSUMABLES 74
6.4.1 HIGH CONSUMPTION OF REAGENTS IN VARIOUS ROUTINE
ASSAYS & TECHNIQUES IS DRIVING THE GROWTH OF THIS SEGMENT 74
6.4.1.1 Media & sera 75
6.4.1.2 Antibodies 77
6.4.1.3 Buffers 79
6.4.1.4 Solvents 80
6.4.1.5 Enzymes, proteins, & peptides 82
6.4.1.6 Probes 83
6.4.1.7 Other reagents & consumables 84

7 NEURODIAGNOSTICS MARKET, BY CONDITION 87
7.1 INTRODUCTION 88
7.2 NEURODEGENERATIVE DISEASES 88
7.2.1 GROWING NUMBER OF NEUROLOGICAL EXAMINATIONS IS SUPPORTING THE GROWTH OF THIS SEGMENT 88
7.3 STROKE 90
7.3.1 GROWING AWARENESS ABOUT STROKE AND ITS TREATMENT OPTIONS TO SUPPORT MARKET GROWTH 90
7.4 EPILEPSY 91
7.4.1 FAVORABLE GOVERNMENT INITIATIVES HAVE RESULTED IN THE INCREASED ADOPTION OF NEURODIAGNOSTIC PRODUCTS 91
7.5 HEADACHE DISORDERS 92
7.5.1 INCREASING INCIDENCE OF MIGRAINES & TENSION HEADACHES TO SUPPORT MARKET GROWTH 92
7.6 SLEEP DISORDERS 93
7.6.1 INCREASING STRESS & UNHEALTHY LIFESTYLES ARE SUPPORTING THE GROWTH OF THIS MARKET SEGMENT 93
7.7 OTHER CONDITIONS 94

8 NEURODIAGNOSTICS MARKET, BY END USER 95
8.1 INTRODUCTION 96
8.2 HOSPITALS & SURGICAL CENTERS 96
8.2.1 HOSPITALS & SURGICAL CENTERS TO DOMINATE THE MARKET OWING TO THEIR HIGH PURCHASING POWER 96
8.3 DIAGNOSTIC LABORATORIES & IMAGING CENTERS 97
8.3.1 GROWING NUMBER OF PRIVATE IMAGING CENTERS TO SUPPORT THE GROWTH OF THIS END-USER SEGMENT 97
8.4 NEUROLOGY CENTERS 98
8.4.1 LOWER COSTS AND SHORTER WAITING PERIODS COMPARED TO HOSPITALS TO DRIVE MARKET GROWTH 98
8.5 AMBULATORY CARE CENTERS 99
8.5.1 HIGH-QUALITY AND LOWER-COST SERVICES OFFERED BY AMBULATORY CARE CENTERS TO DRIVE MARKET GROWTH 99
8.6 RESEARCH LABORATORIES & ACADEMIC INSTITUTES 100
8.6.1 BUDGETARY LIMITATIONS FACED BY SMALL RESEARCH LABORATORIES & ACADEMIC INSTITUTES WILL RESTRAIN MARKET GROWTH 100

9 NEURODIAGNOSTICS MARKET, BY REGION 102
9.1 INTRODUCTION 103
9.2 NORTH AMERICA 103
9.2.1 US 108
9.2.1.1 US dominates the market due to the increased adoption of high-end neurodiagnostic systems 108
9.2.2 CANADA 110
9.2.2.1 Favorable environment for R&D in the field of neurosciences is driving market growth 110
9.3 EUROPE 113
9.3.1 GERMANY 116
9.3.1.1 Germany commands the largest share of the neurodiagnostics market in Europe 116
9.3.2 UK 119
9.3.2.1 Market growth in the UK is mainly driven by the increasing incidence of neurodegenerative diseases 119
9.3.3 FRANCE 121
9.3.3.1 Increasing healthcare expenditure coupled with the high-end medical infrastructure will drive the demand for neurodiagnostic devices 121
9.3.4 ITALY 124
9.3.4.1 Ongoing economic crisis in the country and rising government pressure to reduce healthcare costs may restrain market growth 124
9.3.5 SPAIN 126
9.3.5.1 Increased cost burden on the state-run health insurance system will hinder market growth 126
9.3.6 REST OF EUROPE 128
9.4 ASIA PACIFIC 131
9.4.1 JAPAN 136
9.4.1.1 Favorable reimbursement and rising prevalence of neurological disorders to propel market growth in Japan 136
9.4.2 CHINA 139
9.4.2.1 Government initiatives to modernize healthcare facilities and the rising geriatric population will drive market growth 139
9.4.3 INDIA 141
9.4.3.1 Low entry barriers have made India a prominent market to invest in 141
9.4.4 AUSTRALIA 144
9.4.4.1 Technological advancements and improving healthcare infrastructure will drive the market in Australia 144
9.4.5 SOUTH KOREA 146
9.4.5.1 Rising healthcare spending and medical coverage for neurological disease treatment will propel market growth 146
9.4.6 REST OF ASIA PACIFIC 148
9.5 LATIN AMERICA 151
9.5.1 BRAZIL 155
9.5.1.1 Inadequate accessibility to healthcare has driven the government to undertake corrective measures 155
9.5.2 MEXICO 157
9.5.2.1 Mexico is a prominent medical tourism hub for US patients 157
9.5.3 REST OF LATIN AMERICA 159
9.6 MIDDLE EAST & AFRICA 161
9.6.1 INFRASTRUCTURAL DEVELOPMENT AND GROWING HEALTHCARE EXPENDITURE WILL CONTRIBUTE TO MARKET GROWTH IN THE MEA 161

10 COMPETITIVE LANDSCAPE 165
10.1 OVERVIEW 165
10.2 MARKET SHARE ANALYSIS 166
10.3 COMPETITIVE SCENARIO 167
10.3.1 KEY PRODUCT LAUNCHES 167
10.3.2 KEY EXPANSIONS 167
10.3.3 KEY ACQUISITIONS 168
10.3.4 KEY PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS 168
10.4 COMPETITIVE LEADERSHIP MAPPING 169
10.4.1 VISIONARY LEADERS 170
10.4.2 INNOVATORS 170
10.4.3 DYNAMIC DIFFERENTIATORS 170
10.4.4 EMERGING COMPANIES 170
11 COMPANY PROFILES 172
(Business Overview, Products Offered, Recent Developments, and MnM View)*
11.1 GE HEALTHCARE 172
11.2 PHILIPS HEALTHCARE 175
11.3 SIEMENS HEALTHINEERS 179
11.4 HITACHI, LTD. 183
11.5 CANON, INC. 186
11.6 LIFELINES NEURO COMPANY, LLC 189
11.7 NATUS MEDICAL INCORPORATED 190
11.8 F. HOFFMANN-LA ROCHE AG 193
11.9 FUJIFILM HOLDINGS CORPORATION 195
11.10 MITSAR CO., LTD. 198
11.11 ADVANCED BRAIN MONITORING, INC. 199
11.12 THERMO FISHER SCIENTIFIC, INC. 200
11.13 BIO-RAD LABORATORIES 202
11.14 QIAGEN N.V. 204
11.15 NIHON KOHDEN CORPORATION 207
11.16 OTHER COMPANIES 209
11.16.1 ANT NEURO 209
11.16.2 FONAR CORPORATION 210
11.16.3 FUJIREBIO (A PART OF MIRACA GROUP) 210
11.16.4 DRG INSTRUMENTS GMBH 211
11.16.5 TECAN TRADING AG 212
*Details on Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
12 APPENDIX 213
12.1 DISCUSSION GUIDE 213
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS? SUBSCRIPTION PORTAL 235
12.3 AVAILABLE CUSTOMIZATIONS 237
12.4 RELATED REPORTS 237
12.5 AUTHOR DETAILS 239



List of Figures



FIGURE 1 RESEARCH DESIGN 23
FIGURE 2 BREAKDOWN OF PRIMARIES: NEURODIAGNOSTICS MARKET 26
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 27
FIGURE 4 MARKET SIZE ESTIMATION: NEURODIAGNOSTICS MARKET 28
FIGURE 5 DATA TRIANGULATION METHODOLOGY 29
FIGURE 6 NEURODIAGNOSTICS MARKET, BY PRODUCT, 2019 VS. 2024 (USD MILLION) 32
FIGURE 7 NEURODIAGNOSTICS MARKET SHARE, BY CONDITION, 2019 VS. 2024 33
FIGURE 8 NEURODIAGNOSTICS MARKET SHARE, BY END USER, 2019 VS. 2024 33
FIGURE 9 GEOGRAPHIC SNAPSHOT: NEURODIAGNOSTICS MARKET 34
FIGURE 10 INCREASING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE THE
DEMAND FOR NEURODIAGNOSTIC DEVICES 35
FIGURE 11 DIAGNOSTIC IMAGING SYSTEMS TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 36
FIGURE 12 NORTH AMERICA TO DOMINATE THE NEURODIAGNOSTICS MARKET 37
FIGURE 13 NEURODEGENERATIVE DISEASES SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 38
FIGURE 14 CHINA IS ESTIMATED TO BE THE FASTEST-GROWING MARKET FOR NEURODIAGNOSTICS 39
FIGURE 15 NEURODIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 40
FIGURE 16 NORTH AMERICA: NEURODIAGNOSTICS MARKET SNAPSHOT 104
FIGURE 17 ASIA PACIFIC: NEURODIAGNOSTICS MARKET SNAPSHOT 132
FIGURE 18 KEY DEVELOPMENTS IN THE NEURODIAGNOSTICS MARKET, 2016–2019 165
FIGURE 19 GE HEALTHCARE HELD THE LEADING POSITION IN THE NEURODIAGNOSTICS MARKET IN 2018 166
FIGURE 20 NEURODIAGNOSTICS MARKET (GLOBAL) COMPETITIVE LEADERSHIP
MAPPING, 2018 171
FIGURE 21 GE HEALTHCARE: COMPANY SNAPSHOT 172
FIGURE 22 PHILIPS HEALTHCARE: COMPANY SNAPSHOT 175
FIGURE 23 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT 179
FIGURE 24 HITACHI, LTD.: COMPANY SNAPSHOT 183
FIGURE 25 CANON, INC.: COMPANY SNAPSHOT 186
FIGURE 26 NATUS MEDICAL INCORPORATED: COMPANY SNAPSHOT 190
FIGURE 27 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT 193
FIGURE 28 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT 195
FIGURE 29 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT 200
FIGURE 30 BIO-RAD LABORATORIES: COMPANY SNAPSHOT 202
FIGURE 31 QIAGEN N.V.: COMPANY SNAPSHOT 204
FIGURE 32 NIHON KOHDEN: COMPANY SNAPSHOT 207

 

List of Tables



TABLE 1 NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 47
TABLE 2 DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION) 48
TABLE 3 DIAGNOSTIC IMAGING SYSTEMS MARKET, BY REGION, 2017–2024 (USD MILLION) 48
TABLE 4 DIAGNOSTIC IMAGING SYSTEMS MARKET, BY CONDITION 2017–2024 (USD MILLION) 49
TABLE 5 DIAGNOSTIC IMAGING SYSTEMS MARKET, BY END USER 2017–2024 (USD MILLION) 49
TABLE 6 MRI SYSTEMS MARKET, BY REGION, 2017–2024 (USD MILLION) 50
TABLE 7 MRI SYSTEMS MARKET, BY CONDITION, 2017–2024 (USD MILLION) 50
TABLE 8 MRI SYSTEMS MARKET, BY END USER, 2017–2024 (USD MILLION) 51
TABLE 9 EEG SYSTEMS MARKET, BY REGION, 2017–2024 (USD MILLION) 52
TABLE 10 EEG SYSTEMS MARKET, BY CONDITION, 2017–2024 (USD MILLION) 52
TABLE 11 EEG SYSTEMS MARKET, BY END USER, 2017–2024 (USD MILLION) 53
TABLE 12 CT SCANNERS MARKET, BY REGION, 2017–2024 (USD MILLION) 53
TABLE 13 CT SCANNERS MARKET, BY CONDITION, 2017–2024 (USD MILLION) 54
TABLE 14 CT SCANNERS MARKET, BY END USER, 2017–2024 (USD MILLION) 54
TABLE 15 PET SCANNERS MARKET, BY REGION, 2017–2024 (USD MILLION) 55
TABLE 16 PET SCANNERS MARKET, BY CONDITION, 2017–2024 (USD MILLION) 55
TABLE 17 PET SCANNERS MARKET, BY END USER, 2017–2024 (USD MILLION) 56
TABLE 18 EMG DEVICES MARKET, BY REGION, 2017–2024 (USD MILLION) 56
TABLE 19 EMG DEVICES MARKET, BY CONDITION, 2017–2024 (USD MILLION) 57
TABLE 20 EMG DEVICES MARKET, BY END USER, 2017–2024 (USD MILLION) 57
TABLE 21 ULTRASOUND IMAGING SYSTEMS MARKET, BY REGION 2017–2024 (USD MILLION) 58
TABLE 22 ULTRASOUND IMAGING SYSTEMS MARKET, BY CONDITION 2017–2024 (USD MILLION) 58
TABLE 23 ULTRASOUND IMAGING SYSTEMS MARKET, BY END USER 2017–2024 (USD MILLION) 59
TABLE 24 MEG DEVICES MARKET, BY REGION, 2017–2024 (USD MILLION) 60
TABLE 25 MEG DEVICES MARKET, BY CONDITION, 2017–2024 (USD MILLION) 60
TABLE 26 MEG DEVICES MARKET, BY END USER, 2017–2024 (USD MILLION) 61
TABLE 27 ANGIOGRAPHY SYSTEMS MARKET, BY REGION, 2017–2024 (USD MILLION) 61
TABLE 28 ANGIOGRAPHY SYSTEMS MARKET, BY CONDITION, 2017–2024 (USD MILLION) 62
TABLE 29 ANGIOGRAPHY SYSTEMS MARKET, BY END USER, 2017–2024 (USD MILLION) 62
TABLE 30 OTHER DIAGNOSTIC IMAGING SYSTEMS MARKET, BY REGION 2017–2024 (USD MILLION) 63
TABLE 31 OTHER DIAGNOSTIC IMAGING SYSTEMS MARKET, BY CONDITION 2017–2024 (USD MILLION) 63
TABLE 32 OTHER DIAGNOSTIC IMAGING SYSTEMS MARKET, BY END USER 2017–2024 (USD MILLION) 64
TABLE 33 CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE 2017–2024 (USD MILLION) 64
TABLE 34 CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY REGION 2017–2024 (USD MILLION) 65
TABLE 35 CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY CONDITION 2017–2024 (USD MILLION) 65
TABLE 36 CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY END USER 2017–2024 (USD MILLION) 66
TABLE 37 PCR INSTRUMENTS MARKET, BY REGION, 2017–2024 (USD MILLION) 67
TABLE 38 PCR INSTRUMENTS MARKET, BY CONDITION, 2017–2024 (USD MILLION) 67
TABLE 39 PCR INSTRUMENTS MARKET, BY END USER, 2017–2024 (USD MILLION) 68
TABLE 40 NGS INSTRUMENTS MARKET, BY REGION, 2017–2024 (USD MILLION) 69
TABLE 41 NGS INSTRUMENTS MARKET, BY CONDITION, 2017–2024 (USD MILLION) 69
TABLE 42 NGS INSTRUMENTS MARKET, BY END USER, 2017–2024 (USD MILLION) 70
TABLE 43 SANGER SEQUENCERS MARKET, BY REGION, 2017–2024 (USD MILLION) 71
TABLE 44 SANGER SEQUENCERS MARKET, BY CONDITION, 2017–2024 (USD MILLION) 71
TABLE 45 SANGER SEQUENCERS MARKET, BY END USER, 2017–2024 (USD MILLION) 72
TABLE 46 OTHER CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY REGION 2017–2024 (USD MILLION) 72
TABLE 47 OTHER CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY CONDITION 2017–2024 (USD MILLION) 73
TABLE 48 OTHER CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY END USER 2017–2024 (USD MILLION) 73
TABLE 49 REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION) 74
TABLE 50 REAGENTS & CONSUMABLES MARKET, BY REGION, 2017–2024 (USD MILLION) 74
TABLE 51 REAGENTS & CONSUMABLES MARKET, BY CONDITION 2017–2024 (USD MILLION) 75
TABLE 52 REAGENTS & CONSUMABLES MARKET, BY END USER, 2017–2024 (USD MILLION) 75
TABLE 53 MEDIA & SERA MARKET, BY REGION, 2017–2024 (USD MILLION) 76
TABLE 54 MEDIA & SERA MARKET, BY CONDITION, 2017–2024 (USD MILLION) 76
TABLE 55 MEDIA & SERA MARKET, BY END USER, 2017–2024 (USD MILLION) 77
TABLE 56 ANTIBODIES MARKET, BY REGION, 2017–2024 (USD MILLION) 78
TABLE 57 ANTIBODIES MARKET, BY CONDITION, 2017–2024 (USD MILLION) 78
TABLE 58 ANTIBODIES MARKET, BY END USER, 2017–2024 (USD MILLION) 79
TABLE 59 BUFFERS MARKET, BY REGION, 2017–2024 (USD MILLION) 79
TABLE 60 BUFFERS MARKET, BY CONDITION, 2017–2024 (USD MILLION) 80
TABLE 61 BUFFERS MARKET, BY END USER, 2017–2024 (USD MILLION) 80
TABLE 62 SOLVENTS MARKET, BY REGION, 2017–2024 (USD MILLION) 81
TABLE 63 SOLVENTS MARKET, BY CONDITION, 2017–2024 (USD MILLION) 81
TABLE 64 SOLVENTS MARKET, BY END USER, 2017–2024 (USD MILLION) 81
TABLE 65 ENZYMES, PROTEINS, AND PEPTIDES MARKET, BY REGION 2017–2024 (USD MILLION) 82
TABLE 66 ENZYMES, PROTEINS, AND PEPTIDES MARKET, BY CONDITION 2017–2024 (USD MILLION) 82
TABLE 67 ENZYMES, PROTEINS, AND PEPTIDES MARKET, BY END USER 2017–2024 (USD MILLION) 83
TABLE 68 PROBES MARKET, BY REGION, 2017–2024 (USD MILLION) 83
TABLE 69 PROBES MARKET, BY CONDITION, 2017–2024 (USD MILLION) 84
TABLE 70 PROBES MARKET, BY END USER, 2017–2024 (USD MILLION) 84
TABLE 71 OTHER REAGENTS & CONSUMABLES MARKET, BY REGION 2017–2024 (USD MILLION) 85
TABLE 72 OTHER REAGENTS & CONSUMABLES MARKET, BY CONDITION 2017–2024 (USD MILLION) 85
TABLE 73 OTHER REAGENTS & CONSUMABLES MARKET, BY END USER 2017–2024 (USD MILLION) 86
TABLE 74 NEURODIAGNOSTICS MARKET, BY CONDITION, 2017–2024 (USD MILLION) 88
TABLE 75 NEURODIAGNOSTICS MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2017–2024 (USD MILLION) 90
TABLE 76 NEURODIAGNOSTICS MARKET FOR STROKE, BY REGION 2017–2024 (USD MILLION) 91
TABLE 77 NEURODIAGNOSTICS MARKET FOR EPILEPSY, BY REGION 2017–2024 (USD MILLION) 92
TABLE 78 NEURODIAGNOSTICS MARKET FOR HEADACHE DISORDERS, BY REGION 2017–2024 (USD MILLION) 93
TABLE 79 NEURODIAGNOSTICS MARKET FOR SLEEP DISORDERS, BY REGION 2017–2024 (USD MILLION) 94
TABLE 80 NEURODIAGNOSTICS MARKET FOR OTHER CONDITIONS, BY REGION 2017–2024 (USD MILLION) 94
TABLE 81 NEURODIAGNOSTICS MARKET, BY END USER, 2017–2024 (USD MILLION) 96
TABLE 82 NEURODIAGNOSTICS MARKET FOR HOSPITALS & SURGICAL CENTERS, BY REGION, 2017–2024 (USD MILLION) 97
TABLE 83 NEURODIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES & IMAGING CENTERS, BY REGION, 2017–2024 (USD MILLION) 98
TABLE 84 NEURODIAGNOSTICS MARKET FOR NEUROLOGY CENTERS, BY REGION 2017–2024 (USD MILLION) 99
TABLE 85 NEURODIAGNOSTICS MARKET FOR AMBULATORY CARE CENTERS, BY REGION, 2017–2024 (USD MILLION) 100
TABLE 86 NEURODIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2017–2024 (USD MILLION) 101
TABLE 87 NEURODIAGNOSTICS MARKET, BY REGION, 2017–2024 (USD MILLION) 103
TABLE 88 NORTH AMERICA: NEURODIAGNOSTICS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 105
TABLE 89 NORTH AMERICA: NEURODIAGNOSTICS MARKET, BY PRODUCT 2017–2024 (USD MILLION) 105
TABLE 90 NORTH AMERICA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE 2017–2024 (USD MILLION) 106
TABLE 91 NORTH AMERICA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE 2017–2024 (USD MILLION) 106
TABLE 92 NORTH AMERICA: REAGENTS & CONSUMABLES MARKET, BY TYPE 2017–2024 (USD MILLION) 107
TABLE 93 NORTH AMERICA: NEURODIAGNOSTICS MARKET, BY CONDITION 2017–2024 (USD MILLION) 107
TABLE 94 NORTH AMERICA: NEURODIAGNOSTICS MARKET, BY END USER 2017–2024 (USD MILLION) 108
TABLE 95 US: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 109
TABLE 96 US: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE 2017–2024 (USD MILLION) 109
TABLE 97 US: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE 2017–2024 (USD MILLION) 110
TABLE 98 US: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION) 110
TABLE 99 CANADA: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 111
TABLE 100 CANADA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE 2017–2024 (USD MILLION) 111
TABLE 101 CANADA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE 2017–2024 (USD MILLION) 112
TABLE 102 CANADA: REAGENTS & CONSUMABLES MARKET, BY TYPE 2017–2024 (USD MILLION) 112
TABLE 103 EUROPE: NEURODIAGNOSTICS MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 113
TABLE 104 EUROPE: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 113
TABLE 105 EUROPE: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE 2017–2024 (USD MILLION) 114
TABLE 106 EUROPE: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE 2017–2024 (USD MILLION) 114
TABLE 107 EUROPE: REAGENTS & CONSUMABLES MARKET, BY TYPE 2017–2024 (USD MILLION) 115
TABLE 108 EUROPE: NEURODIAGNOSTICS MARKET, BY CONDITION 2017–2024 (USD MILLION) 115
TABLE 109 EUROPE: NEURODIAGNOSTICS MARKET, BY END USER 2017–2024 (USD MILLION) 116
TABLE 110 GERMANY: NEURODIAGNOSTICS MARKET, BY PRODUCT 2017–2024 (USD MILLION) 117
TABLE 111 GERMANY: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE 2017–2024 (USD MILLION) 117
TABLE 112 GERMANY: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE 2017–2024 (USD MILLION) 118
TABLE 113 GERMANY: REAGENTS & CONSUMABLES MARKET, BY TYPE 2017–2024 (USD MILLION) 118
TABLE 114 UK: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 119
TABLE 115 UK: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE 2017–2024 (USD MILLION) 120
TABLE 116 UK: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE 2017–2024 (USD MILLION) 120
TABLE 117 UK: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION) 121
TABLE 118 FRANCE: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 122
TABLE 119 FRANCE: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE 2017–2024 (USD MILLION) 122
TABLE 120 FRANCE: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE 2017–2024 (USD MILLION) 123
TABLE 121 FRANCE: REAGENTS & CONSUMABLES MARKET, BY TYPE 2017–2024 (USD MILLION) 123
TABLE 122 ITALY: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 124
TABLE 123 ITALY: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE 2017–2024 (USD MILLION) 125
TABLE 124 ITALY: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE 2017–2024 (USD MILLION) 125
TABLE 125 ITALY: REAGENTS & CONSUMABLES MARKET, BY TYPE 2017–2024 (USD MILLION) 126
TABLE 126 SPAIN: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 127
TABLE 127 SPAIN: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE 2017–2024 (USD MILLION) 127
TABLE 128 SPAIN: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE 2017–2024 (USD MILLION) 128
TABLE 129 SPAIN: REAGENTS & CONSUMABLES MARKET, BY TYPE 2017–2024 (USD MILLION) 128
TABLE 130 ROE: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 129
TABLE 131 ROE: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE 2017–2024 (USD MILLION) 129
TABLE 132 ROE: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE 2017–2024 (USD MILLION) 130
TABLE 133 ROE: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION) 130
TABLE 134 ASIA PACIFIC: NEURODIAGNOSTICS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 133
TABLE 135 ASIA PACIFIC: NEURODIAGNOSTICS MARKET, BY PRODUCT 2017–2024 (USD MILLION) 133
TABLE 136 ASIA PACIFIC: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE 2017–2024 (USD MILLION) 134
TABLE 137 ASIA PACIFIC: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE 2017–2024 (USD MILLION) 134
TABLE 138 ASIA PACIFIC: REAGENTS & CONSUMABLES MARKET, BY TYPE 2017–2024 (USD MILLION) 135
TABLE 139 ASIA PACIFIC: NEURODIAGNOSTICS MARKET, BY CONDITION 2017–2024 (USD MILLION) 135
TABLE 140 ASIA PACIFIC: NEURODIAGNOSTICS MARKET, BY END USER 2017–2024 (USD MILLION) 136
TABLE 141 JAPAN: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 137
TABLE 142 JAPAN: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE 2017–2024 (USD MILLION) 137
TABLE 143 JAPAN: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE 2017–2024 (USD MILLION) 138
TABLE 144 JAPAN: REAGENTS & CONSUMABLES MARKET, BY TYPE 2017–2024 (USD MILLION) 138
TABLE 145 CHINA: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 139
TABLE 146 CHINA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE 2017–2024 (USD MILLION) 140
TABLE 147 CHINA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE 2017–2024 (USD MILLION) 140
TABLE 148 CHINA: REAGENTS & CONSUMABLES MARKET, BY TYPE 2017–2024 (USD MILLION) 141
TABLE 149 INDIA: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 142
TABLE 150 INDIA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE 2017–2024 (USD MILLION) 142
TABLE 151 INDIA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE 2017–2024 (USD MILLION) 143
TABLE 152 INDIA: REAGENTS & CONSUMABLES MARKET, BY TYPE 2017–2024 (USD MILLION) 143
TABLE 153 AUSTRALIA: NEURODIAGNOSTICS MARKET, BY PRODUCT 2017–2024 (USD MILLION) 144
TABLE 154 AUSTRALIA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE 2017–2024 (USD MILLION) 145
TABLE 155 AUSTRALIA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE 2017–2024 (USD MILLION) 145
TABLE 156 AUSTRALIA: REAGENTS & CONSUMABLES MARKET, BY TYPE 2017–2024 (USD MILLION) 146
TABLE 157 SOUTH KOREA: NEURODIAGNOSTICS MARKET, BY PRODUCT 2017–2024 (USD MILLION) 147
TABLE 158 SOUTH KOREA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE 2017–2024 (USD MILLION) 147
TABLE 159 SOUTH KOREA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE 2017–2024 (USD MILLION) 148
TABLE 160 SOUTH KOREA: REAGENTS & CONSUMABLES MARKET, BY TYPE 2017–2024 (USD MILLION) 148
TABLE 161 REST OF ASIA PACIFIC: NEURODIAGNOSTICS MARKET, BY PRODUCT 2017–2024 (USD MILLION) 149
TABLE 162 REST OF ASIA PACIFIC: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE 2017–2024 (USD MILLION) 149
TABLE 163 REST OF ASIA PACIFIC: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE, 2017–2024 (USD MILLION) 150
TABLE 164 REST OF ASIA PACIFIC: REAGENTS & CONSUMABLES MARKET, BY TYPE 2017–2024 (USD MILLION) 150
TABLE 165 LATIN AMERICA: NEURODIAGNOSTICS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 151
TABLE 166 LATIN AMERICA: NEURODIAGNOSTICS MARKET, BY PRODUCT 2017–2024 (USD MILLION) 152
TABLE 167 LATIN AMERICA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE 2017–2024 (USD MILLION) 152
TABLE 168 LATIN AMERICA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE 2017–2024 (USD MILLION) 153
TABLE 169 LATIN AMERICA: REAGENTS & CONSUMABLES MARKET, BY TYPE 2017–2024 (USD MILLION) 153
TABLE 170 LATIN AMERICA: NEURODIAGNOSTICS MARKET, BY CONDITION 2017–2024 (USD MILLION) 154
TABLE 171 LATIN AMERICA: NEURODIAGNOSTICS MARKET, BY END USER 2017–2024 (USD MILLION) 154
TABLE 172 BRAZIL: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 155
TABLE 173 BRAZIL: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE 2017–2024 (USD MILLION) 156
TABLE 174 BRAZIL: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE 2017–2024 (USD MILLION) 156
TABLE 175 BRAZIL: REAGENTS & CONSUMABLES MARKET, BY TYPE 2017–2024 (USD MILLION) 157
TABLE 176 MEXICO: NEURODIAGNOSTICS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 157
TABLE 177 MEXICO: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE 2017–2024 (USD MILLION) 158
TABLE 178 MEXICO: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET, BY TYPE 2017–2024 (USD MILLION) 158
TABLE 179 MEXICO: REAGENTS & CONSUMABLES MARKET, BY TYPE 2017–2024 (USD MILLION) 159
TABLE 180 REST OF LATIN AMERICA: NEURODIAGNOSTICS MARKET, BY PRODUCT 2017–2024 (USD MILLION) 159
TABLE 181 REST OF LATIN AMERICA: DIAGNOSTIC IMAGING SYSTEMS MARKET, BY TYPE, 2017–2024 (USD MILLION) 160
TABLE 182 REST OF LATIN AMERICA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET BY TYPE, 2017–2024 (USD MILLION) 160
TABLE 183 REST OF LATIN AMERICA: REAGENTS & CONSUMABLES MARKET, BY TYPE 2017–2024 (USD MILLION) 161
TABLE 184 MIDDLE EAST AND AFRICA: NEURODIAGNOSTICS MARKET, BY PRODUCT 2017–2024 (USD MILLION) 162
TABLE 185 MIDDLE EAST AND AFRICA: DIAGNOSTIC IMAGING SYSTEMS MARKET BY TYPE, 2017–2024 (USD MILLION) 162
TABLE 186 MIDDLE EAST AND AFRICA: CLINICAL DIAGNOSTIC INSTRUMENTS MARKET BY TYPE, 2017–2024 (USD MILLION) 163
TABLE 187 MIDDLE EAST AND AFRICA: REAGENTS & CONSUMABLES MARKET, BY TYPE, 2017–2024 (USD MILLION) 163
TABLE 188 MIDDLE EAST AND AFRICA: NEURODIAGNOSTICS MARKET, BY CONDITION 2017–2024 (USD MILLION) 164
TABLE 189 MIDDLE EAST AND AFRICA: NEURODIAGNOSTICS MARKET, BY END USER 2017–2024 (USD MILLION) 164